Platinum Industries adopts FY26 financials; rejects loan to Rivadu
- Adopted audited standalone and consolidated financial statements for FY26
- Re-appointed Mr. Anup Singh as director retiring by rotation
- Special resolution for loan to Rivadu Lifesciences rejected with 30.23% against votes
- Approved material related party transactions with Platinum Oleo Chemicals and Platinum Stabilizers Egypt

*this image is generated using AI for illustrative purposes only.
Platinum Industries Limited held its sixth Annual General Meeting (AGM) on September 24, 2026. The company adopted the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, alongside reports from the Board of Directors and auditors.
The meeting was conducted via Video Conferencing (VC) and Other Audio-Visual Means (OAVM) in compliance with Ministry of Corporate Affairs and SEBI guidelines. A total of 41 members attended the session, which commenced at 11:00 am and concluded at 11:30 am. Mr. Krishna Dushyant Rana, Chairman cum Managing Director, delivered the address to shareholders, while Chief Financial Officer Mr. Ashok Bothra presented the financial performance.
Board composition and attendance
The following directors were present at the meeting:
| Name | Designation |
|---|---|
| Mr. Krishna Dushyant Rana | Chairman cum Managing Director |
| Ms. Parul Krishna Rana | Executive Director |
| Mr. Anup Singh | Executive Director |
| Mr. Vijuy Ronjan | Non-Executive Independent Director |
| Mr. Samish Dalal | Non-Executive Independent Director |
| Mr. Robin Banerjee | Non-Executive Independent Director |
Mr. Radhakrishnan Iyer, Non-Executive Independent Director and Chairman of the Audit Committee, was granted leave of absence due to a medical emergency. Key management personnel, including Company Secretary Ms. Bhagyashree Mallawat, and representatives from statutory, internal, and secretarial audit firms also attended.
Resolutions passed
Shareholders transacted both ordinary and special business items. The ordinary resolutions included the adoption of financial statements and the re-appointment of Mr. Anup Singh as director, who retired by rotation under Section 152 of the Companies Act, 2013. The ratification of remuneration for the Cost Auditor for FY27 was also approved.
Special business resolutions focused on inter-corporate transactions with subsidiaries. While most related party transactions were approved, one special resolution was defeated:
- Grant of loan or inter-corporate deposit to Platinum Oleo Chemicals Private Limited, a subsidiary where a director is interested: Passed.
- Grant of loan or inter-corporate deposit to Rivadu Lifesciences Private Limited, a subsidiary where a director is interested: Not Passed.
- Material related party transactions with Platinum Stabilizers Egypt LLC: Passed.
- Material related party transactions with Platinum Oleo Chemicals Private Limited: Passed.
Voting results analysis
The scrutinizer’s report revealed that while promoter group votes were excluded for interested resolutions, public shareholders largely supported the management’s proposals. However, Resolution No. 6 regarding Rivadu Lifesciences failed to meet the requisite majority for a special resolution.
| Resolution | Description | Votes in Favour (%) | Votes Against (%) | Result |
|---|---|---|---|---|
| 1 & 2 | Adoption of Standalone & Consolidated FY26 Financials | 100.00% | 0.00% | Passed |
| 3 | Re-appointment of Mr. Anup Singh | 100.00% | 0.00% | Passed |
| 4 | Ratification of Cost Auditor remuneration for FY27 | 100.00% | 0.00% | Passed |
| 5 | Loan/ICD to Platinum Oleo Chemicals Pvt Ltd | 100.00% | 0.00% | Passed |
| 6 | Loan/ICD to Rivadu Lifesciences Pvt Ltd | 69.77% | 30.23% | Not Passed |
| 7 | Material RPT with Platinum Stabilizers Egypt LLC | 100.00% | 0.00% | Passed |
| 8 | Material RPT with Platinum Oleo Chemicals Pvt Ltd | 100.00% | 0.00% | Passed |
What the numbers show
The rejection of Resolution No. 6 highlights a divergence in shareholder sentiment regarding specific subsidiary exposures. While all other related party transactions received unanimous support from non-interested voters, the proposal to extend loans or inter-corporate deposits to Rivadu Lifesciences faced significant opposition. With 30.23% of valid non-interested votes cast against the resolution, it failed to secure the required three-fourths majority for a special resolution. This indicates that minority shareholders exercised their veto power on this specific financial exposure, despite supporting similar transactions with other subsidiaries like Platinum Oleo Chemicals.
Voting and procedural notes
The Statutory Audit Report for standalone and consolidated statements, along with the Secretarial Audit Report for FY26, contained modified opinions and observations. Management responses to these observations were detailed in the Directors' Report and taken as read during the meeting.
Mr. Mayank Arora, Practicing Company Secretary, served as the scrutinizer for the e-voting process. Members who had not voted remotely were given a 15-minute window to cast their votes after the meeting's conclusion. Results are expected to be declared within two working days.
Historical Stock Returns for Platinum Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.18% | -0.15% | -8.04% | -4.42% | -28.50% | -8.10% |
How will the rejection of the inter-corporate deposit to Rivadu Lifesciences impact its operational liquidity and future capital requirements?
What specific financial or governance concerns drove minority shareholders to oppose the Rivadu Lifesciences loan while supporting similar transactions with other subsidiaries?
Will Platinum Industries seek alternative financing structures for Rivadu Lifesciences or reduce its exposure to this subsidiary following the shareholder veto?


































